Cell and Gene Therapy Medical Affairs Summit
Tuesday, December 03, 2024 from 08:00am to 03:30pm
Wyndham Boston Beacon Hill, 5 Blossom Street
USD 2199.00 - USD 4397.00
Welcome to the Cell and Gene Therapy Medical Affairs Summit!
Delivering Impactful Education to Transform Patient Outcomes
Introducing the Cell and Gene Therapy Medical Affairs Summit, the premier event highlighting the essential role of medical affairs in delivering therapies to patients. Explore how traditional approaches are being revolutionized to tackle the unique challenges of cell and gene therapy drug development. Here, the fusion of scientific and clinical expertise with strategic commercial vision creates opportunities for transformative breakthroughs!
This exclusive summit brings together Chief Medical Officers and senior leaders from medical affairs, medical communications, field medical, medical science liaisons, and more. Whether you're nearing IND submission or preparing for BLA approval, this gathering of brilliant minds offers unparalleled networking and insights from organizations like Adaptimmune, Autolus Therapeutics, Bristol Myers Squibb, bluebird bio, Caribou Biosciences, Editas Medicine, Orchard Therapeutics, and more.
See Full Agenda - https://ter.li/4bq5sc
Register Online (Earlybird Savings Expiring) - https://ter.li/afobyb
URLs:
Tickets: https://go.evvnt.com/2569187-2?pid=91
Brochure: https://go.evvnt.com/2569187-3?pid=91
Prices:
Drug Developer Tickets | Conference + 2 Workshops: USD 3497.00,
Drug Developer Tickets | Conference + 1 Workshop: USD 3048.00,
Drug Developer Tickets | Conference Only: USD 2599.00,
Start-Up and Academic Tickets | Conference + 2 Workshops: USD 2897.00,
Start-Up and Academic Tickets | Conference + 1 Workshop: USD 2548.00,
Start-Up and Academic Tickets | Conference Only: USD 2199.00,
Standard Tickets | Conference + 2 Workshops: USD 4397.00,
Standard Tickets | Conference + 1 Workshop: USD 3848.00,
Standard Tickets | Conference Only: USD 3299.00
Speakers: AiThi Sprinkle | Associate Director, Medical Science Liaison | Vor Bio, Alexander Maurer | Executive Director, WW Cell Therapy Franchise Medical Lead | Bristol Myers Squibb, Alicia O’Connor | Head of Field Medical | Adaptimmune, Amin Boroujerdi | Director, Medical Affairs | Aspen Neuroscience, Angela Tom | Senior Director, Medical Affairs | Editas Medicine, Darren Johnson | Medical Science Liaison | Vor Bio, Eileen Sawyer | Former Senior Vice President, Clinical and Medical Affairs | Independent Expert, Ike Ogbaa | Former Vice President, Global Head of Medical Affairs | bluebird bio, Jason Lott | Vice President, Global Integrated Evidence Generation, Cell and Gene Therapy | Bayer, Jeff Haroldson | Executive Director, Head of Medical Affairs, North America | Tenaya Therapeutics, Katie Snell | Associate Director, Global Medical Affairs | Orchard Therapeutics, Kent Christopherson | Executive Director and Head, Global Medical Affairs | Orchard Therapeutics, Oscar Segurado | Former Chief Medical Officer | Independent Expert, Preeti Joshi | Senior Director, Head of Medical Affairs | BlueRock Therapeutics, Rohita Sharma | Senior Director, Global Patient Insights and Solutions, Medical Affairs | Alexion Pharmaceuticals, Scott Miller | Vice President, U.S. Medical Affairs | Autolus Therapeutics, Sujan Sivasubramaniya | Head of Medical Affairs and Patient Advocacy, UK and Ireland | CSL Behring, Tonia Nesheiwat | Vice President, Medical Affairs and Project Leadership | Caribou Biosciences, Warren Rizzo | Scientific and Medical Affairs Consultant | ImmPACT Bio